Fonte: Current Pharmaceutical Design. Unidade: FMRP
Assuntos: CANNABIS (COMPONENTES;FARMACOLOGIA), ANTAGONISMO DE DROGAS, MODELOS ANIMAIS DE DOENÇAS, ESQUIZOFRENIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEVIN, Raquel et al. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design, v. 18, n. 32, p. 4960-4965, 2012Tradução . . Acesso em: 16 nov. 2025.APA
Levin, R., Almeida, V., Peres, F. F., Calzavara, M. B., Silva, N. D. da, Suiama, M. A., et al. (2012). Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design, 18( 32), 4960-4965.NLM
Levin R, Almeida V, Peres FF, Calzavara MB, Silva ND da, Suiama MA, Niigaki ST, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design. 2012 ; 18( 32): 4960-4965.[citado 2025 nov. 16 ]Vancouver
Levin R, Almeida V, Peres FF, Calzavara MB, Silva ND da, Suiama MA, Niigaki ST, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design. 2012 ; 18( 32): 4960-4965.[citado 2025 nov. 16 ]
